Literature DB >> 25845034

The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations.

Paolo Prandoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25845034      PMCID： PMC4385064          DOI： 10.2450/2015.0002-15

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  15 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).

Authors:  V Pengo; L Crippa; A Falanga; G Finazzi; F Marongiu; G Palareti; D Poli; S Testa; E Tiraferri; A Tosetto; A Tripodi; C Manotti
Journal:  Thromb Haemost       Date:  2011-09-22       Impact factor: 5.249

Review 3.  Venous thromboembolism in 2013: the advent of the novel oral anticoagulants.

Authors:  Paolo Prandoni
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

Review 4.  Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.

Authors:  Paolo Prandoni; Sofia Barbar; Marta Milan; Elena Campello; Luca Spiezia; Chiara Piovella; Raffaele Pesavento
Journal:  Thromb Haemost       Date:  2014-08-14       Impact factor: 5.249

5.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

Review 6.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

Authors:  Nick van Es; Michiel Coppens; Sam Schulman; Saskia Middeldorp; Harry R Büller
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

7.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

Review 8.  Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.

Authors:  G Alotaibi; K Alsaleh; C Wu; M S Mcmurtry
Journal:  Int Angiol       Date:  2014-08       Impact factor: 2.789

Review 9.  Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jonathan Douxfils; Fanny Buckinx; François Mullier; Valentine Minet; Véronique Rabenda; Jean-Yves Reginster; Philippe Hainaut; Olivier Bruyère; Jean-Michel Dogné
Journal:  J Am Heart Assoc       Date:  2014-06-06       Impact factor: 5.501

10.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.

Authors:  Martin H Prins; Anthonie Wa Lensing; Rupert Bauersachs; Bonno van Bellen; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Gary E Raskob; Scott D Berkowitz; Philip S Wells
Journal:  Thromb J       Date:  2013-09-20
View more
  7 in total

1.  The use of novel oral anticoagulants: the debate continues!

Authors:  Massimo Franchini; Claudio Velati
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

Review 2.  How we treat bleeding associated with direct oral anticoagulants.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giancarlo M Liumbruno; Massimo Franchini
Journal:  Blood Transfus       Date:  2016-01-19       Impact factor: 3.443

Review 3.  Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.

Authors:  Davide Imberti; Fulvio Pomero; Daniela Mastroiacovo
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

Review 4.  The evolution of anticoagulant therapy.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Carlo Bonfanti; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

5.  Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy.

Authors:  Kenichi Nitta; Hiroshi Imamura; Akihiro Yashio; Satoko Kashima; Katsunori Mochizuki
Journal:  Case Rep Crit Care       Date:  2016-10-31

6.  ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism.

Authors:  Carlo D'Agostino; Pietro Zonzin; Iolanda Enea; Michele Massimo Gulizia; Walter Ageno; Piergiuseppe Agostoni; Michele Azzarito; Cecilia Becattini; Amedeo Bongarzoni; Francesca Bux; Franco Casazza; Nicoletta Corrieri; Michele D'Alto; Nicola D'Amato; Andrea Maria D'Armini; Maria Grazia De Natale; Giovanni Di Minno; Giuseppe Favretto; Lucia Filippi; Valentina Grazioli; Gualtiero Palareti; Raffaele Pesavento; Loris Roncon; Laura Scelsi; Antonella Tufano
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

7.  ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention.

Authors:  Iolanda Enea; Loris Roncon; Michele Massimo Gulizia; Michele Azzarito; Cecilia Becattini; Amedeo Bongarzoni; Franco Casazza; Claudio Cuccia; Carlo D'Agostino; Matteo Rugolotto; Marco Vatrano; Eugenio Vinci; Paride Fenaroli; Dario Formigli; Paolo Silvestri; Federico Nardi; Maria Cristina Vedovati; Marino Scherillo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.